BeiGene Announces that RATIONALE 303 Trial of Tislelizumab in Non-Small Cell Lung Cancer Met the Primary Endpoint of Overall Survival at Interim Analysis
RATIONALE 303 is a global Phase 3 trial of BeiGene’s anti-PD-1 antibody tislelizumab compared to docetaxel in the second- or...






